कंपनी का अवलोकन
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical enterprise dedicated to developing therapeutics specifically for rare cardiovascular conditions. The company functions within the healthcare sector and the biotechnology industry, a domain characterized by high research and development expenditures aimed at creating novel treatments for unmet medical needs. According to the available data, the company possesses a market capitalization of $12.46M, while specific figures for annual revenue and employee count are not disclosed in the provided records. This limited market capitalization relative to its stage of development indicates that the firm is a small-cap entity, suggesting it is in a phase where capital allocation is primarily directed toward advancing its clinical pipeline rather than generating significant commercial sales or scaling operations.
वित्तीय स्वास्थ्य
The financial statements reveal that the company reported a net income of $-13,237,362 and an EBITDA of $-13,454,303, while revenue data is not available in the current dataset. The substantial negative gap between the reported net income and EBITDA, even without precise revenue figures to calculate gross profit directly, implies a significant cost structure where operating expenses, likely dominated by research, development, and administrative costs, are consuming the majority of the company's resources. Furthermore, the free cash flow stands at $-7,784,269, which indicates that the company is burning cash at a rapid pace to fund its operations and scientific endeavors. The company holds cash reserves of $4.01M against zero reported debt, creating a distinct financial profile. All three margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, which is typical for early-to-mid-stage biotechnology firms that have not yet achieved commercial revenue or have revenues that do not cover direct costs, effectively rendering traditional profitability metrics inapplicable. The balance sheet appears structurally conservative in terms of leverage, as the company carries no debt, though the lack of a debt-to-equity figure prevents a precise ratio calculation. Additionally, the current ratio is 2.72, a metric that suggests the company maintains a strong position regarding short-term liquidity, possessing sufficient current assets to cover its short-term liabilities with a comfortable buffer. Finally, the return on equity is -260.1% and the return on assets is -116.4%, metrics that reveal that the company is currently diluting shareholder and asset value through its heavy investment spending rather than generating returns, a common characteristic for pre-revenue biotech entities.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is not applicable due to the lack of net income, while the forward P/E is listed as -1.27, implying that future earnings expectations are also negative or that the valuation model relies on non-GAAP measures or anticipated cash flows rather than historical profits. A price-to-book ratio of 4.24 indicates that the market is valuing the company at a significant premium over its book value, reflecting the high perceived value of its intellectual property and clinical pipeline rather than its tangible assets. Since revenue data is unavailable, the price-to-sales ratio cannot be calculated, and the EV/EBITDA stands at -0.63, which suggests the valuation is driven by enterprise value metrics that account for the negative earnings trajectory typical of development-stage companies. The stock has traded between a 52-week high of $17.50 and a 52-week low of $4.21, placing the current trading environment within a wide historical range that reflects high volatility inherent in the biotechnology sector. With a beta of 1.55, the stock exhibits price volatility that is 55% higher than the broader market, indicating that investor sentiment and sector-specific news can cause disproportionate swings in the share price relative to large-cap benchmarks.
Growth & Income
Specific figures for revenue growth year-over-year and earnings growth year-over-year are not available in the provided data, preventing a direct comparison of earnings expansion versus revenue expansion. As a company with a dividend yield of N/A and a payout ratio of 0.0%, Cadrenal Therapeutics does not distribute dividends to shareholders. This non-dividend status is consistent with the company's strategic choice to reinvest all available earnings, including cash reserves, back into the development of Tecarfarin and other therapeutics for rare cardiovascular conditions rather than paying out income. Consequently, the overall growth and income profile is defined entirely by capital appreciation potential and the progression of its clinical trials, as there is no current income stream generated from dividends for investors to rely upon.